Study Randomizer 

Study: Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients (SECR-02)

This study uses Study Randomizer. Last updated: 2021-05-09

Link to study information: https://www.clinicaltrials.gov/ct2/show/NCT04838821

Country: Costa Rica

Start date: 2021-03-21

Abstract: Evaluate the efficacy and safety of three different doses of an anti-SARS-CoV-2 hyperimmune equine serum formulation (S-type) as an addition to the standard therapeutic approach in adult hospitalized patients with a diagnosis of moderate or severe COVID-19, radiological findings consistent with pneumonia and a symptom onset period not exceeding 10 days. A total of 156 patients will be included and randomly divided into four groups, each group will receive a different dose of the investigational drug.

Back to the list of studies: Studies overview